WUXI BIOLOGICS Aktie

 

WUXI BIO (02269.HK) has issued a positive profit alert for 2H25, according to a CLSA research report.The company estimated its revenue to have logged a basically in-line growth of 17% YoY, while its net profit and adjusted net profit will have increased by 38% and 31% YoY to RMB2.6 billion and RMB3.7 billion, both significantly ......

WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing. In a positive profit alert filed with the Hong Kong stock exchange on Wednesday, the company said profit attributable to equity shareholders would reach about 4.91 billion yuan (US$710 million), while revenue is set to climb 16.7 per cent to 21.79 billion yuan. Shares rose......

WUXI BIO (02269.HK) opened 3.55% higher today (11th) at HKD41.44, with a trading volume of 530,500 shares, involving HKD21.8422 million.The company has issued a positive profit alert. On an IFRS basis, it estimated its 2025 revenue to have grown by around 16.7% YoY to RMB21.79 billion, while its profit/ profit attributable to it......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

SHANGHAI, Feb. 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the third year the company has received the rating's highest level of recognition. EcoVadis is among the world's most trusted and......

The Chinese stock market rebounded in January, with the HSI/ MSCI China Index swelling by 6.9%/ 5% MoM each, UOB Kay Hian said. However, the overall gains were limited by the 'National Team' led by Central Huijin selling US$68 billion. The best performers in the broker's January picks with a Buy rating are WUXI BIO ......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - WuXi Biologics (2269. HK,WXIBF), a Contract Research, Development, and Manufacturing Organisation, announced on Tuesday that it has signed a license and resea......

SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)......

SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel......

SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research,......

The People's Bank of China (PBOC) announced yesterday (15th) measures including lowering interest rates on various structural monetary policy tools. This morning, the HSI opened 171 points or 0.6% higher at 27,094.The HSCEI opened 63 points or 0.7% higher at 9,330. The HSTECH opened 55 points or 0.9% higher at 5,883.KUAISHOU......

WUXI BIO (02269.HK) opened 3.4% lower today (16th) at HKD38.66, with a pre-market trading volume of 151 million shares, involving HKD5.814 billion. WUXI BIO announced that its major shareholder, Biologics Holdings, had entered into a Block Trade Agreement with Morgan Stanley (Placing Agent), pursuant to which the Placing Agent h......

WUXI BIO (02269.HK) announced that its major shareholder, Biologics Holdings, had entered into a Block Trade Agreement with Morgan Stanley (Placing Agent), pursuant to which the Placing Agent had agreed to place 150 million existing shares of the Company (representing approximately 3.63% of the total issued share capital of the ......

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients Complex modalities are WuXi Biologics' core growth engine,......

BIODLINK-B (01875.HK) received a takeover bid from WUXI XDC (02268.HK) at a 60% premium. After resuming trading this morning (15th), BIODLINK-B's stock price once peaked at HKD3.97. It last traded at HKD3.93, up 57.2%, with a volume of 2.8 million shares and a turnover of HKD11.0256 million.BIODLINK-B, WUXI BIO (02269.HK), a......

Daiwa released a research report raising its target price for WUXI BIO (02269.HK) from $35.5 to $42, with rating kept at Buy. The broker lifted its 2025-2027 EPS forecasts for WUXI BIO by 1-5%, based on higher project signing expectations and continued operational leverage, and raised its 2028-2032 revenue forecasts by 3-7%, bas......

WUXI BIO (02269.HK) released a document to be presented at the 44th JPM Healthcare Conference tomorrow (14th) listing a number of ongoing projects that exceeded JPMorgan's expectations, according to JPMorgan's research report. Several operational highlights are viewed positively, including the Company's successful ac......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

UBS has published a research report reiterating a Buy rating on WUXI XDC (02268.HK) for its leading position in the bioconjugate CRDMO platform, continuous capacity expansion, and controllable geopolitical risks. The broker's target price was HKD89.5.In 2025, WUXI BIO (02269.HK), WUXI XDC's parent company, added a total ......